Potential commission cap regulation
Regulatory changes could cap commission rates, impacting distribution costs and growth. Management awaits clarity but believes single expense limit is preferable.
Niva Bupa Health · risk themes across the available quarters.
Bear-case history
Regulatory changes could cap commission rates, impacting distribution costs and growth. Management awaits clarity but believes single expense limit is preferable.
Industry growth may moderate as the GST tailwind fades. Management expects stabilization at 17-19% CAGR, but near-term volatility is possible.
Group health loss ratio was ~60.5% for FY26, and IFRS loss components on onerous contracts could signal underwriting risk.